Truist analyst Richard Newitter lowered the firm’s price target on Stryker (SYK) to $392 from $407 and keeps a Hold rating on the shares following Q3 results with “mixed quality” earnings upside. Some key organizational revenue drivers fell short, but hips/knees picked up and record Mako placements could be suggestive of Mako 4 gaining steam, Truist told investors in a research note. The firm’s estimates inch upwards, and with the November 13 investor day coming up, Truist said it will get a sense of management’s long-term targets and whether there could be faster growth prospects to support a higher multiple.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker’s Strong Q3 Performance and Raised Guidance Justify Buy Rating
- Stryker price target lowered to $405 from $410 at Evercore ISI
- Stryker’s Strategic Growth and M&A Focus Earns Buy Rating from Analyst
- Stryker price target raised to $410 from $408 at BTIG
- Stryker’s Strong Revenue Growth and Margin Expansion Drive Buy Rating